11-cis-retinal

11-cis-ret·i·nal

(ret'i-năl),
The isomer of retinaldehyde that can combine with an opsin to form either iodopsin or rhodopsin; it is formed from 11-trans-retinal by retinal isomerase.
Synonym(s): neoretinal b

11-cis-ret·i·nal

(sis'ret'i-năl)
The isomer of retinaldehyde that can combine with opsin to form rhodopsin; it is formed from 11-trans-retinal by retinal isomerase.
References in periodicals archive ?
QLT's synthetic retinoid program is a replacement for 11-cis-retinal and is under development for the treatment of retinal diseases caused by gene mutations that interfere with the availability of 11-cis-retinal.
11-cis-retinal is a key biochemical component of the visual retinoid cycle, the deficiency of which is associated with certain inherited or age-related retinal diseases, including Leber Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP).
Mutations in the genes for retinal pigment epithelium protein 65 (RPE65) and lecithin:retinol acyltransferase (LRAT) result in an inadequate production of 11-cis-retinal and occur in approximately 10% of patients with LCA, and to a lesser extent in Retinitis Pigmentosa (RP), another inherited retinal dystrophy.
The compound is expected to slow the regeneration of 11-cis-retinal in the retina, and has been demonstrated to have beneficial effect in several preclinical models of retinal degeneration by stopping the accumulation of retinoid-related toxic byproducts including A2E.
QLT091001 is an orally administered synthetic retinoid replacement for 11-cis-retinal, which is a key biochemical component of the visual retinoid cycle, and is under investigation for the treatment of LCA and RP.
The basis for using synthetic retinoids as replacement therapy for conditions where genetic defects result in deficiency of 11-cis-retinal is founded on experiments in mouse genetic models, including those developed in the laboratory of Dr.
Two different gene mutations (Retinal pigment epithelium protein 65 (RPE65) and lecithin-retinol acyltransferase (LRAT) result in an inadequate production of 11-cis-retinal and occur in approximately 10% of patients with LCA and to a lesser extent in RP.
QLT091001 is a replacement for 11-cis-retinal which is an essential component of the retinoid-rhodopsin cycle and visual function.
NASDAQ: QLTI; TSX: QLT) announced today that it has initiated a Phase I safety study in healthy adults of QLT091001, an orally administered synthetic retinoid replacement therapy for 11-cis-retinal, which is a key biochemical component of the visual retinoid cycle.